This HTML5 document contains 47 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
wdthttp://www.wikidata.org/prop/direct/
wdtnhttp://www.wikidata.org/prop/direct-normalized/
schemahttp://schema.org/
rdfshttp://www.w3.org/2000/01/rdf-schema#
skoshttp://www.w3.org/2004/02/skos/core#
wikibasehttp://wikiba.se/ontology#
phttp://www.wikidata.org/prop/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n10http://rdf.ncbi.nlm.nih.gov/pubchem/reference/
xsdhhttp://www.w3.org/2001/XMLSchema#
n11http://dx.doi.org/10.1002/
wdshttp://www.wikidata.org/entity/statement/
wdhttp://www.wikidata.org/entity/

Statements

Subject Item
wd:Q72658167
rdf:type
wikibase:Item
schema:description
scientific article published on 01 November 1993 im November 1993 veröffentlichter wissenschaftlicher Artikel artículu científicu espublizáu en payares de 1993 наукова стаття, опублікована в листопаді 1993 wetenschappelijk artikel article scientifique publié en 1993
p:P577
wds:Q72658167-0D2ADC1E-CB61-409D-9B60-865E5DF3215E
wdt:P577
1993-11-01T00:00:00Z
p:P2093
wds:Q72658167-2AA459CE-4640-479C-88BB-11108C117732 wds:Q72658167-04A94CE1-D260-459A-BDAB-ECD622910A79 wds:Q72658167-8C4B90DB-59DD-4A42-B12C-2E2C327A9978
wdt:P2093
P Hannonen M Oka M Hakola
rdfs:label
Sulfasalazine in early rheumatoid arthritis. A 48-week double-blind, prospective, placebo-controlled study Sulfasalazine in early rheumatoid arthritis. A 48-week double-blind, prospective, placebo-controlled study
skos:prefLabel
Sulfasalazine in early rheumatoid arthritis. A 48-week double-blind, prospective, placebo-controlled study Sulfasalazine in early rheumatoid arthritis. A 48-week double-blind, prospective, placebo-controlled study
schema:name
Sulfasalazine in early rheumatoid arthritis. A 48-week double-blind, prospective, placebo-controlled study Sulfasalazine in early rheumatoid arthritis. A 48-week double-blind, prospective, placebo-controlled study
p:P50
wds:Q72658167-64F66E65-5DC0-45A4-A881-A87ED1540E0B
wdt:P50
wd:Q59169124
p:P1476
wds:Q72658167-5790D7E4-BE33-4841-B834-12E54679D665
wdt:P1476
Sulfasalazine in early rheumatoid arthritis. A 48-week double-blind, prospective, placebo-controlled study
p:P304
wds:Q72658167-9E9C0C6F-ACDE-46E7-9CBD-6D0689CC32F3
wdt:P304
1501-1509
p:P31
wds:Q72658167-C553D30A-E496-4E28-9757-121A638077E1
wdt:P31
wd:Q13442814
p:P921
wds:Q72658167-A099544C-BADE-48A5-A7E5-542EE96E90DB wds:Q72658167-A1BE917D-4797-4BC4-9DCA-3D444F880DFF wds:Q72658167-B5E8553D-AD53-4B56-A6C2-0539F38DB5A5
wdt:P921
wd:Q187255 wd:Q269829 wd:Q420035
p:P698
wds:Q72658167-B0038C7F-C9CD-4AA6-AF08-DD4F8C5AC5F6
wdtn:P698
n10:7902092
wdt:P698
7902092
p:P1433
wds:Q72658167-F451D4C5-FA75-4424-ADC8-ADA74054AABF
wdt:P1433
wd:Q23929027
p:P433
wds:Q72658167-37B1A249-C332-45D6-ABDD-82981A0F661E
p:P478
wds:Q72658167-C50A7979-7308-4922-9746-4DFADD487644
wdt:P433
11
wdt:P478
36
p:P356
wds:Q72658167-9AD8CE8F-BF66-4F00-80D6-363F067D0F0B
wdtn:P356
n11:ART.1780361104
wdt:P356
10.1002/ART.1780361104